DK3004174T3 - Heteromultimerer med reduceret eller nedreguleret effektorfunktion - Google Patents
Heteromultimerer med reduceret eller nedreguleret effektorfunktion Download PDFInfo
- Publication number
- DK3004174T3 DK3004174T3 DK14803370.7T DK14803370T DK3004174T3 DK 3004174 T3 DK3004174 T3 DK 3004174T3 DK 14803370 T DK14803370 T DK 14803370T DK 3004174 T3 DK3004174 T3 DK 3004174T3
- Authority
- DK
- Denmark
- Prior art keywords
- multimates
- heater
- reduced
- effector function
- regulated effector
- Prior art date
Links
- 239000012636 effector Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361829973P | 2013-05-31 | 2013-05-31 | |
| PCT/CA2014/050507 WO2014190441A1 (en) | 2013-05-31 | 2014-05-30 | Heteromultimers with reduced or silenced effector function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3004174T3 true DK3004174T3 (da) | 2019-07-22 |
Family
ID=51987817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14803370.7T DK3004174T3 (da) | 2013-05-31 | 2014-05-30 | Heteromultimerer med reduceret eller nedreguleret effektorfunktion |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11098105B2 (enExample) |
| EP (1) | EP3004174B1 (enExample) |
| JP (1) | JP6567506B2 (enExample) |
| KR (1) | KR102332303B1 (enExample) |
| CN (1) | CN105849129A (enExample) |
| AU (1) | AU2014273817B2 (enExample) |
| BR (1) | BR112015029788B1 (enExample) |
| CA (1) | CA2913370C (enExample) |
| DK (1) | DK3004174T3 (enExample) |
| ES (1) | ES2736326T3 (enExample) |
| RU (1) | RU2655439C2 (enExample) |
| WO (1) | WO2014190441A1 (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3056568B1 (en) | 2006-03-31 | 2021-09-15 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| CN103328632A (zh) | 2010-11-30 | 2013-09-25 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
| AU2013289883B2 (en) * | 2012-07-13 | 2018-11-01 | Zymeworks Bc Inc. | Bispecific asymmetric heterodimers comprising anti-CD3 constructs |
| WO2014030728A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | FcγRIIb特異的Fc領域改変体 |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| CN113621057A (zh) | 2013-04-02 | 2021-11-09 | 中外制药株式会社 | Fc区变体 |
| ES3030987T3 (en) | 2013-11-27 | 2025-07-03 | Zymeworks Bc Inc | Bispecific antigen-binding constructs targeting her2 |
| DK3223848T3 (da) | 2014-11-27 | 2025-03-03 | Zymeworks Bc Inc | Fremgangsmåder til anvendelse af bispecifikke antigenbindingskonstrukter målrettet her2 |
| IL278014B2 (en) | 2014-12-19 | 2023-10-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use |
| SG10201907215QA (en) | 2015-02-05 | 2019-09-27 | Chugai Pharmaceutical Co Ltd | Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof |
| EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE |
| JP7082604B2 (ja) | 2016-03-21 | 2022-06-08 | マレンゴ・セラピューティクス，インコーポレーテッド | 多重特異性および多機能性分子ならびにその使用 |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| DK3478830T3 (da) | 2016-07-01 | 2024-05-21 | Resolve Therapeutics Llc | Optimerede binucleasefusioner og metoder |
| CN109689099B (zh) | 2016-08-05 | 2023-02-28 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| MX2019008199A (es) | 2017-01-06 | 2019-11-25 | Avidity Biosciences Llc | Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon. |
| SG11201907321TA (en) | 2017-02-07 | 2019-09-27 | Daiichi Sankyo Co Ltd | Anti-gprc5d antibody and molecule comprising the antibody |
| WO2018151820A1 (en) | 2017-02-16 | 2018-08-23 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
| SI3583120T1 (sl) | 2017-02-17 | 2023-02-28 | Denali Therapeutics Inc. | Inženirani polipeptidi, ki vezujejo transferinske receptorje |
| CN110719915A (zh) * | 2017-05-25 | 2020-01-21 | 百时美施贵宝公司 | 包含经修饰的重链恒定区的抗体 |
| WO2018222901A1 (en) | 2017-05-31 | 2018-12-06 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| CA3068841A1 (en) | 2017-07-03 | 2019-01-10 | Torque Therapeutics, Inc. | Fusion molecules targeting immune regulatory cells and uses thereof |
| GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| MX2020002070A (es) | 2017-08-22 | 2020-03-24 | Sanabio Llc | Receptores solubles de interferon y usos de los mismos. |
| WO2019113393A1 (en) | 2017-12-06 | 2019-06-13 | Avidity Biosciences Llc | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| PL3765525T3 (pl) | 2018-03-13 | 2023-12-27 | Zymeworks Bc Inc. | Koniugaty biparatopowe przeciwciało anty-her2 – lek i sposoby stosowania |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| WO2019178364A2 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| TWI887899B (zh) | 2018-03-15 | 2025-06-21 | 日商中外製藥股份有限公司 | 對茲卡病毒具有交叉反應性的抗登革病毒抗體之用途 |
| WO2019241430A2 (en) * | 2018-06-12 | 2019-12-19 | Angiex, Inc. | Antibody-oligonucleotide conjugates |
| CN112955465A (zh) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| SG11202103568PA (en) * | 2018-10-23 | 2021-05-28 | Magenta Therapeutics Inc | Fc silenced antibody drug conjugates (adcs) and uses thereof |
| CN119661722A (zh) | 2019-02-21 | 2025-03-21 | 马伦戈治疗公司 | 结合t细胞相关癌细胞的多功能分子及其用途 |
| AU2020226904B2 (en) | 2019-02-21 | 2025-05-01 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| JP7706373B2 (ja) | 2019-02-21 | 2025-07-11 | マレンゴ・セラピューティクス，インコーポレーテッド | カルレティキュリンに結合する多機能性分子およびその使用 |
| CA3130628A1 (en) | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
| JP2022522007A (ja) * | 2019-02-27 | 2022-04-13 | アンジーエックス・インコーポレーテッド | 抗ｔｍ４ｓｆ１抗体を含む抗体薬物コンジュゲートおよびそれを使用する方法 |
| AU2020263487A1 (en) | 2019-04-25 | 2021-12-16 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| TWI879770B (zh) * | 2019-05-30 | 2025-04-11 | 美商安進公司 | 工程改造鉸鏈區以驅動抗體二聚化 |
| GB2609554B (en) | 2020-01-03 | 2025-08-20 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| WO2021138407A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| WO2021142086A1 (en) | 2020-01-08 | 2021-07-15 | Synthis Therapeutics, Inc. | Alk5 inhibitor conjugates and uses thereof |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| TW202144572A (zh) | 2020-03-19 | 2021-12-01 | 美商亞維代堤生物科學公司 | 治療臉肩胛肱骨肌肉失養症之組合物及方法 |
| CN120058957A (zh) * | 2020-03-30 | 2025-05-30 | 国立大学法人三重大学 | 双特异性抗体 |
| JP2023523011A (ja) | 2020-04-24 | 2023-06-01 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| WO2022046920A2 (en) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| KR20230074487A (ko) | 2020-08-26 | 2023-05-30 | 마렝고 테라퓨틱스, 인크. | Trbc1 또는 trbc2를 검출하는 방법 |
| AU2021331076A1 (en) | 2020-08-26 | 2023-04-06 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| TW202246331A (zh) | 2021-01-13 | 2022-12-01 | 美商威特拉公司 | 人源化補體５ａ受體１抗體及其使用方法 |
| KR20240004462A (ko) | 2021-04-08 | 2024-01-11 | 마렝고 테라퓨틱스, 인크. | Tcr에 결합하는 다기능성 분자 및 이의 용도 |
| US20240383998A1 (en) * | 2021-04-20 | 2024-11-21 | Korea University Research And Business Foundation | Asymmetric antibody with improved cytotoxicity against cancer cells |
| US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| EP4608515A1 (en) | 2022-10-25 | 2025-09-03 | Seismic Therapeutic, Inc. | Variant igg fc polypeptides and uses thereof |
| WO2024258967A1 (en) | 2023-06-13 | 2024-12-19 | Synthis Therapeutics, Inc. | Anti-cd5 antibodies and their uses |
| WO2025064435A1 (en) * | 2023-09-19 | 2025-03-27 | Imaginab, Inc. | Antigen binding constructs directed to integrin αvβ6 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US7951917B1 (en) * | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| NZ532526A (en) | 2001-10-25 | 2007-01-26 | Genentech Inc | Compositions comprising a glycoprotein having a Fc region |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| RU2390527C2 (ru) * | 2002-09-27 | 2010-05-27 | Ксенкор, Инк. | АНТИТЕЛО, СОДЕРЖАЩЕЕ Fc-ВАРИАНТНУЮ ЧАСТЬ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АНТИТЕЛО, И СПОСОБ ЛЕЧЕНИЯ МЛЕКОПИТАЮЩЕГО |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| EP3321282A1 (en) | 2002-09-27 | 2018-05-16 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス，インコーポレーテッド | 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法 |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US8399618B2 (en) | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
| EP2275448A3 (en) | 2003-12-19 | 2013-02-06 | Genentech, Inc. | Monovalent antibody fragments useful as therapeutics |
| US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
| CA2602663A1 (en) | 2005-03-31 | 2006-10-05 | Xencor, Inc. | Fc variants with optimized properties |
| US20070190063A1 (en) | 2005-08-19 | 2007-08-16 | Bahjat Keith S | Antibody-mediated enhancement of immune response |
| EP3392273A1 (en) | 2007-05-30 | 2018-10-24 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| EP2631297B1 (en) | 2008-05-15 | 2017-04-12 | National Research Council Of Canada | Process, vectors and engineered cell lines for enhanced large-scale transfection |
| EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
| JP2013511281A (ja) * | 2009-11-23 | 2013-04-04 | アムジェン インコーポレイテッド | 単量体抗体Ｆｃ |
| ES2609043T3 (es) | 2009-11-30 | 2017-04-18 | Janssen Biotech, Inc. | Anticuerpos mutantes Fc con funciones de efecto abladas |
| EP2552957A4 (en) | 2010-03-29 | 2013-11-20 | Zymeworks Inc | ANTIBODIES WITH REINFORCED OR SUPPRESSIVE ACTIVE FUNCTION |
| US9150663B2 (en) * | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
| WO2011143545A1 (en) * | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| AU2011325833C1 (en) * | 2010-11-05 | 2017-07-13 | Zymeworks Bc Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| CN112812184A (zh) * | 2011-02-25 | 2021-05-18 | 中外制药株式会社 | FcγRIIb特异性Fc抗体 |
| WO2012133782A1 (ja) | 2011-03-30 | 2012-10-04 | 中外製薬株式会社 | 抗原結合分子の血漿中滞留性と免疫原性を改変する方法 |
| JP5972915B2 (ja) * | 2011-03-16 | 2016-08-17 | アムジエン・インコーポレーテツド | Ｆｃ変異体 |
| SI2691417T2 (sl) | 2011-03-29 | 2025-05-30 | Roche Glycart Ag | FC variante protitelesa |
| CN109517059B (zh) * | 2011-06-30 | 2023-03-28 | 中外制药株式会社 | 异源二聚化多肽 |
| WO2013012733A1 (en) * | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
| WO2013063702A1 (en) * | 2011-11-04 | 2013-05-10 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| JP6571527B2 (ja) | 2012-11-21 | 2019-09-04 | ウーハン ワイゼットワイ バイオファルマ カンパニー リミテッドＷｕｈａｎ Ｙｚｙ Ｂｉｏｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． | 二重特異性抗体 |
| US10128092B2 (en) | 2013-05-31 | 2018-11-13 | Micromass Uk Limited | Compact mass spectrometer |
| MX2016000272A (es) | 2013-07-12 | 2016-08-03 | Zymeworks Inc | Construcciones de unión a los antígenos cd19 y cd3 biespecificos. |
-
2014
- 2014-05-30 BR BR112015029788-9A patent/BR112015029788B1/pt active IP Right Grant
- 2014-05-30 CN CN201480039387.XA patent/CN105849129A/zh active Pending
- 2014-05-30 AU AU2014273817A patent/AU2014273817B2/en not_active Ceased
- 2014-05-30 US US14/893,503 patent/US11098105B2/en active Active
- 2014-05-30 JP JP2016515582A patent/JP6567506B2/ja active Active
- 2014-05-30 ES ES14803370T patent/ES2736326T3/es active Active
- 2014-05-30 KR KR1020157036704A patent/KR102332303B1/ko active Active
- 2014-05-30 CA CA2913370A patent/CA2913370C/en active Active
- 2014-05-30 RU RU2015152084A patent/RU2655439C2/ru active
- 2014-05-30 DK DK14803370.7T patent/DK3004174T3/da active
- 2014-05-30 EP EP14803370.7A patent/EP3004174B1/en active Active
- 2014-05-30 WO PCT/CA2014/050507 patent/WO2014190441A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| RU2655439C2 (ru) | 2018-05-28 |
| JP2016520598A (ja) | 2016-07-14 |
| JP6567506B2 (ja) | 2019-08-28 |
| CN105849129A (zh) | 2016-08-10 |
| BR112015029788B1 (pt) | 2024-01-02 |
| KR20160023721A (ko) | 2016-03-03 |
| KR102332303B1 (ko) | 2021-11-26 |
| BR112015029788A2 (pt) | 2017-09-26 |
| EP3004174A4 (en) | 2017-01-04 |
| RU2015152084A (ru) | 2017-07-06 |
| HK1223376A1 (en) | 2017-07-28 |
| AU2014273817A1 (en) | 2015-12-03 |
| AU2014273817B2 (en) | 2019-03-14 |
| EP3004174B1 (en) | 2019-04-17 |
| US20160102135A1 (en) | 2016-04-14 |
| CA2913370C (en) | 2022-12-13 |
| US11098105B2 (en) | 2021-08-24 |
| ES2736326T3 (es) | 2019-12-27 |
| CA2913370A1 (en) | 2014-12-04 |
| EP3004174A1 (en) | 2016-04-13 |
| WO2014190441A9 (en) | 2015-02-05 |
| WO2014190441A1 (en) | 2014-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3004174T3 (da) | Heteromultimerer med reduceret eller nedreguleret effektorfunktion | |
| BR302014000411S1 (pt) | Configuração aplicada em ventilador | |
| BR302013004498S1 (pt) | Configuração aplicada em ventilador | |
| BR302013004415S1 (pt) | Configuração aplicada em ventilador | |
| HUE053511T2 (hu) | Párologtató eszközt tartalmazó rendszer | |
| BR302014000270S1 (pt) | Configuração aplicada em ventilador | |
| BR302014001719S1 (pt) | Configuração aplicada em para-brisa | |
| EP2989885A4 (en) | HARVESTER | |
| BR302014001119S1 (pt) | Configuração aplicada em copo | |
| EP2964517A4 (en) | ROWING | |
| BR302014002700S1 (pt) | Configuração aplicada em para-brisa | |
| EP2839822A4 (en) | Defrosting device | |
| EP2980573A4 (en) | BIOSENSOR | |
| DK3051953T3 (da) | Varmluft-stativovn | |
| DK2789926T3 (da) | Ventilatorvarmer | |
| NO20131519A1 (no) | Kontaktvarmer | |
| EP2970860A4 (en) | Genetically modified bacteria | |
| DE102013201943B8 (de) | Heizvorrichtung | |
| DK2995796T3 (da) | Totaktsmotor med længdeskylning | |
| BR302013005396S1 (pt) | Configuração aplicada em ventilador | |
| BR302013001233S1 (pt) | Configuração aplicada em hélice de ventilador | |
| FI20130147L (fi) | Yhdistelmäkiuas | |
| UA24767S (uk) | Кріплення опалювальної панелі | |
| ES1079212Y (es) | Abanico de accionamiento solar | |
| UA27690S (uk) | Грілка гумова |